Shoulder Innovations, Inc.
NYSE:SIMedical - Specialties
-$0.13 today
- Market cap
- $432.04M
- Beta
- -1.07
- P/E (TTM)
- -8.4
- EPS (TTM)
- -$2.13
Volume 0.09M
Average 0.10M
SI Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Shoulder Innovations, Inc.NYSE: SI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $1.13M rose 69.5% year over year, behind the +210.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 15.5% from the prior quarter.
Context
- Depreciation & amortization amounted to 6.8% of revenue in FY2025, down 0.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth recovers from +69.5% toward the trailing-twelve-month pace of +210.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.21M USD
- Year-over-year change
- +46.1%
- 2-year CAGR
- +39.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.21M | +46.1% |
| FY2024 | 2024-12-31 | 2.2M | +33.8% |
| FY2023 | 2023-12-31 | 1.64M | — |
Depreciation & Amortization vs competitors
How SI compares with its peers on the latest reported figures
- SI's LTM Mar 2026 depreciation & amortization of $3.67M is the 6th highest of the 11 companies compared; the peer median is $3.84M.
- Its year-over-year change of +210.5% is the highest of 11, against a peer median of -1.5%.
- Depreciation & amortization amounts to 6.8% of revenue for SI, versus a peer median of 5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.37M | -2.6% | -4.2% | 5.8% | |
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| FY2025 | $9.21M | +14.5% | +23.3% | 8.5% | |
| LTM Mar 2026 | $6.32M | -43.5% | +23.7% | — | |
| LTM Mar 2026 | $4.93M | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $3.67M | +210.5% | — | 6.8% | |
| LTM Mar 2026 | $2.74M | -56.6% | -11.6% | 2.3% | |
| LTM Mar 2026 | $1.59M | +32.3% | +10.5% | 3.6% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $262.3K | +45.1% | +30.9% | — |
| LTM Mar 2026 | $122K | -6.2% | -36.3% | 0.2% | |
| LTM Mar 2026 | $42K | -31.1% | -31.1% | — | |
| Peer median (excluding SI) | $3.84M | -1.5% | +5.5% | 5.8% | |
Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 19.27M | 31.62M | 47.32M |
| Cost of Revenue | 4M | 7.28M | 11.12M |
| Gross Profit | 15.27M | 24.34M | 36.2M |
| Gross Margin | 79.2% | 77.0% | 76.5% |
| Research & Development | 3.02M | 4.49M | 7.73M |
| Selling, General & Admin | 23.11M | 34.51M | 54.77M |
| Operating Expenses | 26.13M | 38.99M | 62.5M |
| Depreciation & Amortization | 1.64M | 2.2M | 3.21M |
| EBITDA | (10.25M) | (12.11M) | (37.08M) |
| EBITDA Margin | -53.2% | -38.3% | -78.4% |
| Operating Income | (10.86M) | (14.65M) | (26.3M) |
| Operating Margin | -56.4% | -46.3% | -55.6% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 761K | 1.32M | 70K |
| Other Income / Expenses | (1.79M) | (966K) | (14.06M) |
| Income Before Tax | (12.66M) | (15.62M) | (40.36M) |
| Pre-Tax Margin | -65.7% | -49.4% | -85.3% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (12.66M) | (15.62M) | (40.36M) |
| Net Margin | -65.7% | -49.4% | -85.3% |
| EPS (Basic) | (0.63) | (0.77) | (1.96) |
| EPS (Diluted) | (0.63) | (0.77) | (1.96) |
| Weighted Avg Shares | 19.92M | 19.92M | 20.63M |
| Weighted Avg Shares (Diluted) | 19.92M | 19.92M | 20.63M |
Shoulder Innovations, Inc.
NYSE:SI
Intrinsic Alpha fair value
Locked
Current Price
$20.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.